Timothy Warbington Discloses Investment at Creative Medical Technology with 13.7% Stake

Creative Medical Technology Holdings (NASDAQ: CELZ) issued a mid-year update. It said Olastrocel (CELZ-201) has WHO-approved naming and reported positive interim 180-day ADAPT trial results; the FDA cleared an expanded cohort for patients using <90 mg/day morphine equivalents. Ultrasome™ pilot data showed a 93% primary endpoint response. The CELZ-Biodefense Atlas program advanced to nationwide AI-enabled veteran data collection.

Creative Medical Technology Holdings (CELZ) said it secured about $4.5M in gross proceeds via warrant exercises and related stock purchases. The company will exercise warrants for up to 2,790,340 shares and investors will buy 5,580,680 shares at $1.60/share, with new five-year warrants issued. Closing is expected June 30, 2026.

Creative Medical Technology (CELZ) said the FDA cleared an amended protocol to expand its ADAPT trial of Olastrocel (CELZ-201) for chronic lower back pain. The company will add 15 patients using <90 mg morphine equivalents/day; the new cohort is 85% enrolled and uses its AI pain-medication monitoring. Creative Medical cited positive 180-day interim results and a DSMB report of no significant adverse events, and said it is preparing for Phase 3 discussions.

Netflix film chief Dan Lin is leaving after nearly three years, following Bela Bajaria's departure. Peter Rice will temporarily lead the film division. The changes come amid growth concerns and competition. Netflix co-CEO Ted Sarandos acknowledged slower-than-desired growth. The company is also cutting 6% of its workforce and will report Q3 results on Tuesday.

Constellation Energy (CEG) reported $24.7B in debt as of June 2026, up from $8.3B a year prior. Its stock fell 32.4% over the past year, underperforming the S&P 500. The company's debt is 25.3% of its market value, slightly above the S&P 500's 20.0%. Free cash flow was negative in the last three quarters, but cash from operations rose to $4.2B in the year to June 2026. Management expects $5.9B from asset sales related to the Calpine acquisition.

Venu Holdings' William Hodgson will step down as President on October 13, 2026, and assist with transition until December 1, 2026. The change is mutual and not due to policy disagreements. No successor has been named, with responsibilities shifting to existing management. Severance details are not finalized.